Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients.

ABSTRACT: The COVID-19 outbreak is now one of the most critical crises to manage for most of national healthcare systems in the world. The situation is complicated by the absence of vaccines and authorized pharmacological treatments, except for remdesivir. In this context, many medicaments, including different Ebola and HIV antivirals, are used off-label in the hospital wards as life-treating medicines for COVID-19 patients. Authorized medicaments manipulation is sometimes necessary because they are not always formulated to be administered to non-cooperative patients or they are in shortage. It is this the case of the fixed combination of lopinavir/ritonavir, which was extensively used in the first phase of the outbreak inducing a shortage of the oral solution available in the EU market. This work p

SUBMITTER: Zanon D 

PROVIDER: S-EPMC7582040 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature